Sandoz to acquire respiratory generics maker Oriel
Sandoz plans to acquire U.S. pharmaceuticals company Oriel Therapeutics, which the Novartis division said would give it exclusive rights to a portfolio of generic drug candidates and related technologies in the inhalable respiratory drug market. Terms of the deal weren’t disclosed.